长期控制>9年使用美格斯特酸-莱特醇:转移性子宫内膜腺癌病例报告
Lixia Liu1, Lina Ma1, Lu Yang2
1Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, Taiyuan, China.
Frontiers in oncology
|March 12, 2026
概括
荷尔蒙受体阳性转移性子宫内膜癌可以用美格斯特酸和列特治疗. 这种组合疗法可以在选择的患者中提供长期的疾病控制.
科学领域:
- 妇科瘤学 妇科瘤学
- 内分泌学 在内分泌学.
- 医学瘤学 医学瘤学
背景情况:
- 激素受体阳性 (HR+) 子宫内膜癌 (EC) 通常对内分泌治疗有反应.
- 临床效益持续时间通常是有限的,特别是在转移性或复发性疾病中.
研究的目的:
- 介绍一个患有转移性HR高的子宫内膜癌的病例研究.
- 为了评估megestrol酸盐加上letrozole在治疗晚期疾病中的有效性.
主要方法:
- 一名54岁的女性患有转移性HR-高EC,接受了美格斯特酸盐和莱特.
- 对治疗反应进行了108个月的监测,包括剂量修改和中止期间.
主要成果:
- 患者最初在38个月内实现了稳定的疾病,然后在恢复治疗后又持续了49个月.
- 剂量调整和再升级表明持续的疾病控制与最小的毒性.
- 总体生存时间达到108个月,持续稳定的疾病.
结论:
- 完全剂量的美格斯特酸加上莱特醇可能会在HR高的转移性EC中诱导持久的抗瘤活性.
- 这种组合值得对管理晚期子宫内膜癌的潜在验证.
相关概念视频
Hormonal Control of the Ovarian Cycle
7.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
7.4K
Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K


